ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics
Authors:
- Lauriane VelotLVLauriane Velot
- Lydia GhouinemLGLydia Ghouinem
- Mohamed AbdelkarimMohamed Abdelkarim
- Benjamin Pierre BouchetBBBenjamin Pierre Bouchet
- Anny-Claude LuissintALAnny-Claude Luissint
- Imène BouhlelIBImène Bouhlel
- Marina MorelMMMarina Morel
- Elène SapharikasESElène Sapharikas
- Anne Di TommasoATAnne Di Tommaso
- Stéphane HonoréSHStéphane Honoré
- Diane BraguerDBDiane Braguer
- 30 April 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (9) , 2905-2915
Abstract
Metastasis, a fatal complication of breast cancer, does not fully benefit from available therapies. In this study, we investigated whether ATIP3, the major product of 8p22 MTUS1 gene, may be a novel biomarker and therapeutic target for metastatic breast tumors. We show that ATIP3 is a prognostic marker for overall survival among patients with breast cancer. Notably, among metastatic tumors, low ATIP3 levels associate with decreased survival of the patients. By using a well-defined experimental mouse model of cancer metastasis, we show that ATIP3 expression delays the time-course of metastatic progression and limits the number and size of metastases in vivo. In functional studies, ATIP3 silencing increases breast cancer cell migration, whereas ATIP3 expression significantly reduces cell motility and directionality. We report here that ATIP3 is a potent microtubule-stabilizing protein whose depletion increases microtubule dynamics. Our data support the notion that by decreasing microtubule dynamics, ATIP3 controls the ability of microtubule tips to reach the cell cortex during migration, a mechanism that may account for reduced cancer cell motility and metastasis. Of interest, we identify a functional ATIP3 domain that associates with microtubules and recapitulates the effects of ATIP3 on microtubule dynamics, cell proliferation, and migration. Our study is a major step toward the development of new personalized treatments against metastatic breast tumors that have lost ATIP3 expression. Cancer Res; 73(9); 2905–15. ©2013 AACR.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Regulation of cell migration by dynamic microtubulesSeminars in Cell & Developmental Biology, 2011
- Beyond taxanes: the next generation of microtubule-targeting agentsBreast Cancer Research and Treatment, 2011
- Down‐regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinomaMolecular Oncology, 2011
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapseClinical & Experimental Metastasis, 2008
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Genomic assessments of the frequent loss of heterozygosity region on 8p21.3∼p22 in head and neck squamous cell carcinomaCancer Genetics and Cytogenetics, 2007
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001